サンプル依頼リスト カート
  • English
  • Korean
表紙：肺炎桿菌感染症の世界市場-2023年～2030年
市場調査レポート
商品コード
1352189

肺炎桿菌感染症の世界市場-2023年～2030年

Global Klebsiella Pneumoniae Infections Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肺炎桿菌感染症の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

肺炎桿菌感染症は、病原性細菌である肺炎桿菌によって引き起こされ、様々な病状を引き起こす可能性があります。肺炎桿菌はグラム陰性菌の一種で、土壌、水、植物などの環境中に普通に存在します。人体、特に消化管や呼吸器系にも生息することがあります。

健康な人では無害であることが多いですが、特に免疫系が低下している人や基礎疾患を持つ人では、様々な感染症を引き起こす可能性があります。これは肺炎桿菌がカプセルと呼ばれる厚く粘着性のある物質を産生し、身体の免疫防御を回避するのに役立つからです。

このような感染症は、罹患した身体の部位によって様々な形で現れます。肺炎桿菌は、発熱、咳、呼吸困難などの症状を引き起こす肺感染症を引き起こすことがあります。尿路感染症は、細菌が尿路に侵入することで発症し、排尿痛、頻尿、下腹部痛などの症状を引き起こします。血流感染症は、発熱、悪寒、血圧低下などを引き起こします。創傷感染症では、創傷部位が赤く腫れ、膿が形成されることがあります。

感染症の重症度は様々で、抗生物質で簡単に治療できる軽症のものから、入院して集中治療を必要とする重症のものまであります。場合によっては、肺炎桿菌感染症は抗生物質に耐性を持つこともあり、治療がより困難になります。したがって、肺炎桿菌感染症の疑いがある場合は、医師の診察を受けることが重要です。

さらに、肺炎桿菌の抗生物質耐性株の有病率の上昇、肺炎桿菌感染症の新規治療のための研究の増加、薬剤の臨床試験の増加は、予測期間中に市場を牽引すると予想される要因です。

ダイナミクス

肺炎桿菌感染症を管理するための治療オプションの進歩が市場成長を促進すると予想される

2022年8月18日、Springer誌は、肺炎桿菌は菌血症、尿路感染症、肝膿瘍、肺炎などさまざまな感染症を引き起こす日和見グラム陰性病原体であるとの論文を発表しました。この病原体はますます蔓延しつつあり、多剤耐性肺炎桿菌株は世界保健機関（WHO）によって公衆衛生上の重大な脅威として認識されています。これらの菌株がもたらす脅威は、利用可能な治療法の限界により、これらの感染症と効果的に闘うことが困難であることから、特に懸念されています。

有望な治療法もいくつかあります。米国FDAは、特に肺炎桿菌感染症に焦点を当てたcUTIの治療薬としてメロペネム／バボルバクタムを承認しました。現在進行中の臨床試験で、この治療法は臨床的治癒率を高め、他の標準的な治療法よりも忍容性が高い可能性が示されています。一方、セフタジジム/アビバクタムは、これらの尿路結石に対する適切な治療法を選択する際に考慮すべきもう一つの重要な治療選択肢です。

カルバペネム耐性肺炎桿菌に対抗するために、他にもいくつかの新しい治療法が有望視されています。イミペネム／スルバクタム、プラゾマイシン、エラバサイクリン、セフィデロコール、アズトレオナム・アビバクタムはすべて、これらの耐性株に対して有効であると報告されています。これらの治療法は、現在進行中の抗生物質耐性菌との闘いにおける重要な前進であり、将来的にはこれらの感染症をよりよく管理するのに役立つであろう。したがって、上記の要因により、市場は予測期間中に拡大すると予想されます。

肺炎桿菌の治療に焦点を当てた臨床試験数の増加が市場成長を促進する見込み

Phramongkutklao College of Medicine and Hospitalは、シラパコーン大学と共同で、カルバペネム耐性肺炎桿菌（CRKP）感染患者の憂慮すべき死亡率に対処するための介入臨床試験を実施するという重要な課題に取り組んでいます。

この研究は、重症患者の転帰を決定する上で、薬物動態学的／薬力学的（PK/PD）考察によって調整される適切な抗生物質療法の重要な役割を調査することを目的としています。このような症例では、標準的な抗生物質の投与量では望ましいPK/PD目標を達成できない可能性があることは周知の事実です。そこで本研究では、モンテカルロシミュレーションを用いてPK/PDを調整した用量の抗生物質を投与された重症患者と、標準的な用量の抗生物質を投与された過去の重症患者の臨床転帰を比較することを目的とします。

介入モデルには、PK/PDの原則による投与量の最適化が含まれます。本試験は2023年5月に開始され、2024年6月までに完了する予定です。このイニシアチブは、公衆衛生上の緊急課題である重症患者におけるCRKP感染症に対するより効果的な抗生物質治療戦略の緊急の必要性に対処するものです。

本試験は、CRKPに感染した重症患者の臨床転帰を改善するためのPK/PD調整抗生物質療法の可能性について、本質的な洞察を提供するものと期待されます。これは、世界の公衆衛生に深刻な脅威をもたらす抗菌薬耐性との戦いにおいて、極めて重要な前進です。本研究で得られた知見は、ヘルスケア専門家および政策立案者に貴重な情報を提供し、CRKP感染症に対するより効果的な治療プロトコルの開発を導くものです。したがって、上記の要因により、市場は予測期間中に拡大すると予想されます。

SERSスペクトルのディープラーニング分析による多剤耐性肺炎桿菌の迅速な予測が市場成長を牽引すると期待される

肺炎桿菌は、重篤で治療困難な感染症を引き起こす可能性があるため、臨床環境において重大な脅威となる、非常に懸念される病原体です。世界的に多剤耐性が増加しているこの病原体は、感染を予防・制御するための臨床診断における迅速かつ正確な同定の必要性をさらに高めています。

しかし、従来の診断法や分子生物学的診断法には限界があり、病原体の適時診断が大幅に遅れる可能性があります。この課題に対処するため、研究者らは、肺炎桿菌感染症を診断するための、新規で、ラベルフリー、非侵襲的、低コストな方法を開発するための研究を行っています。この研究では、表面増強ラマン散乱（SERS）分光法を利用して、ポリミキシン耐性肺炎桿菌（PRKP）、カルバペネム耐性肺炎桿菌（CRKP）、カルバペネム感受性肺炎桿菌（CSKP）など、薬剤耐性プロファイルが異なる121株の肺炎桿菌のSERSスペクトルを作成しました。

肺炎桿菌の薬剤耐性を予測するために、SERSスペクトルを畳み込みニューラルネットワーク（CNN）を用いて計算解析しました。CNNモデルはアテンションメカニズムにより強化され、99.46%という高い予測精度を達成しました。また、5重クロスバリデーションのロバストネススコアは98.87%でした。

これらの結果は、ディープラーニングアルゴリズムの支援により、肺炎桿菌の薬剤耐性予測におけるSERS分光法の精度と頑健性を検証するものです。本研究は、PRKP、CRKP、およびCSKP株の識別と予測に成功し、臨床診断のための貴重なツールを提供しました。したがって、上記の要因のおかげで、市場は予測期間にわたって牽引すると予想されます。

KPC産生肺炎桿菌に対する限られた治療オプションが市場成長の妨げになる見込み

肺炎桿菌による感染症は、特に多剤耐性の場合、治療が困難となる可能性があります。肺炎桿菌を特異的に標的とする新しい抗生物質の開発ペースが遅いため、効果的な治療戦略が妨げられる可能性があります。

KPC産生肺炎桿菌の場合、治療の選択肢が限られているため、この課題はさらに強調されます。このような場合、微生物検査室では、どの抗生物質が感染症の治療に有効かを判断するために、特定の検査を実施しなければなりません。KPC-KP感染症患者には、分離株に対して活性を示す2種類以上の薬剤による治療を受けることが推奨されます。このアプローチは、このような患者の生存率を改善することが示されています。したがって、上記の要因により、予測期間中、市場は低迷すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 肺炎桿菌の治療オプションの進歩
      • 肺炎桿菌の治療に焦点を当てた臨床試験数の増加
      • SERSスペクトルのディープラーニング分析による多剤耐性肺炎桿菌の迅速予測
    • 抑制要因
      • KPC産生肺炎桿菌に対する限られた治療オプション
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • 特許分析
  • ロシア・ウクライナ紛争分析
  • DMIの見解

第6章 COVID-19分析

第7章 感染タイプ別

  • 肺炎
  • 尿路感染症（UTI）
  • 血流感染
  • 腹腔内感染
  • 創傷感染

第8章 薬剤クラス別

  • β-ラクタム薬
    • クラブラン酸
    • スルバクタム
    • タゾバクタム
    • アビバクタム
    • バボールバクタム
  • アミノグリコシド
    • ゲンタマイシン
    • トブラマイシン
    • アミカシン
    • ストレプトマイシン
    • その他
  • キノロン系抗菌薬
    • シプロフロキサシン（シプロ）
    • レボフロキサシン
    • モキシフロキサシン
    • オフロキサシン
    • ノルフロキサシン
    • ジェミフロキサシン
    • その他
  • セファロスポリン
    • セフトリアキソン
    • セフォタキシム
  • カルバペネム系抗生物質
    • イミペネム/シラスタチン
    • メロペネム
    • ドリペネム
    • エルタペネム

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Pfizer Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Novartis AG
  • AdvaCare Pharma
  • Merck & Co., Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals, Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Aurobindo Pharma Colombia
  • Par Pharmaceutical
  • AbbVie
  • Actavis

第13章 付録

目次
Product Code: PH6950

Overview

Klebsiella pneumoniae infections are caused by the pathogenic bacterium Klebsiella pneumonia, which can lead to a range of medical conditions. Klebsiella pneumonia is a type of Gram-negative bacteria that is commonly found in the environment, including soil, water, and plants. It can also inhabit the human body, particularly in the gastrointestinal tract and respiratory system.

While it is often harmless in healthy individuals, it has the potential to cause various infections, especially in people with compromised immune systems or underlying health conditions. This is because Klebsiella pneumoniae can produce a thick, sticky substance called a capsule that helps it evade the body's immune defenses.

These infections can manifest in different ways, depending on the affected body part. Klebsiella pneumoniae can cause pneumonia, a lung infection that can cause symptoms such as fever, cough, and difficulty breathing. Urinary tract infections, caused by bacteria entering the urinary tract, can cause symptoms such as painful urination, frequent urination, and lower abdominal pain. Bloodstream infections can cause fever, chills, and low blood pressure. Wound infections can cause redness, swelling, and pus formation at the site of the wound.

The severity of the infection can vary, from mild cases that can be easily treated with antibiotics to more severe cases that require hospitalization and intensive medical care. In some cases, Klebsiella pneumoniae infections can also be resistant to antibiotics, making them more difficult to treat. Therefore, it is important to seek medical attention if you suspect you may have a Klebsiella pneumoniae infection.

Furthermore, the rising prevalence of antibiotic-resistant strains of Klebsiella pneumoniae, the increasing research for the novel treatment of Klebsiella pneumoniae infections, and increasing clinical trials of drugs are the factors expected to drive the market over the forecast period.

Dynamics

Advancements in Treatment Options for Managing Klebsiella pneumoniae Infections are Expected to Drive the Market Growth

On August 18, 2022, Springer published an article stating that Klebsiella pneumoniae is an opportunistic gram-negative pathogen that can cause various infectious diseases, including bacteremia, urinary tract infections, liver abscesses, and pneumonia. This pathogen is becoming increasingly prevalent, and multidrug-resistant K. pneumoniae strains have been identified as a critical public health threat by the World Health Organization. The threat posed by these strains is particularly concerning because the limitations of available treatment options make it difficult to effectively combat these infections.

There are some promising treatment options available. The US FDA has approved meropenem/vaborbactam for the treatment of cUTIs, with a particular focus on K. pneumoniae infections. Ongoing clinical trials have indicated that this treatment can enhance clinical cure rates and may be better tolerated than other standard therapies. Meanwhile, ceftazidime/avibactam is another important treatment option to consider when choosing the appropriate treatment for these UTIs.

Several other newer treatment options have shown promise in combating carbapenem-resistant K. pneumoniae. Imipenem/sulbactam, plazomicin, eravacycline, cefiderocol, and aztreonam-avibactam have all been reported to be active against these resistant strains. These treatments represent an important step forward in the ongoing fight against antibiotic-resistant bacteria and may help us to better manage these infections in the future. Hence, owing to the above factors, the market is expected to drive over the forecast period.

The Rising Number of Clinical Trials Focused on Addressing Klebsiella Pneumoniae Infections is Expected to Drive Market Growth

The Phramongkutklao College of Medicine and Hospital, in collaboration with Silpakorn University, has taken on the critical task of conducting an interventional clinical trial to address the alarming mortality rate among patients infected with Carbapenem-resistant Klebsiella pneumoniae (CRKP).

This study is aimed at investigating the critical role of appropriate antibiotic therapy adjusted by pharmacokinetic/pharmacodynamic (PK/PD) considerations in determining outcomes for critically ill patients. It is a well-known fact that standard antibiotic doses might not be enough to attain the desired PK/PD targets in these cases. Therefore, this research aims to compare clinical outcomes between critically ill patients who receive antibiotics with PK/PD-adjusted doses using Monte Carlo simulation and historical critically ill patients who were treated with standard practices.

The intervention model involves dose optimization through PK/PD principles. The study is anticipated to commence in May 2023, with an estimated completion by June 2024. This initiative addresses the urgent need for more effective antibiotic treatment strategies for CRKP infections in critically ill patients, which is a pressing public health concern.

The trial is expected to provide essential insights into the potential of PK/PD-adjusted antibiotic therapy in improving clinical outcomes for critically ill patients infected with CRKP. This is a crucial step forward in the battle against antimicrobial resistance, which poses a severe threat to global public health. The findings of this study will provide valuable information to healthcare professionals and policymakers alike, guiding the development of more effective treatment protocols for CRKP infections. Hence, owing to the above factors, the market is expected to drive over the forecast period.

Rapid Prediction of Multidrug-Resistant Klebsiella Pneumoniae through Deep Learning Analysis of SERS Spectra is Expected to Drive Market Growth

Klebsiella pneumoniae is a highly concerning pathogen that poses a significant threat in clinical settings due to its potential to cause serious and difficult-to-treat infections. The pathogen's increasing multidrug resistance worldwide further exacerbates the need for rapid and accurate identification in clinical diagnosis to prevent and control infection.

However, conventional and molecular methods for diagnosis are limited and can significantly delay the timely diagnosis of the pathogen. To address this challenge, researchers conducted a study to develop a novel, label-free, noninvasive, and low-cost method for diagnosing K. pneumoniae infections. The study utilized surface-enhanced Raman scattering (SERS) spectroscopy to generate SERS spectra for 121 K. pneumoniae strains with varying drug resistance profiles, including polymyxin-resistant K. pneumoniae (PRKP), carbapenem-resistant K. pneumoniae (CRKP), and carbapenem-sensitive K. pneumoniae (CSKP).

To predict the drug resistance of K. pneumoniae strains, the SERS spectra were computationally analyzed using the convolutional neural network (CNN). The CNN model was enhanced with an attention mechanism, resulting in prediction accuracy as high as 99.46%. The model also exhibited a robustness score of 5-fold cross-validation at 98.87%.

These findings validate the accuracy and robustness of SERS spectroscopy in predicting drug resistance of K. pneumoniae strains, due to the assistance of deep learning algorithms. The study successfully discriminated against and predicted PRKP, CRKP, and CSKP strains to provide a valuable tool for clinical diagnosis. Hence, owing to the above factors, the market is expected to drive over the forecast period.

Limited Treatment Options for KPC-Producing Klebsiella pneumoniae is Expected to Hamper the Market Growth

Infections caused by Klebsiella pneumoniae can prove to be a challenge to treat, especially when they are multidrug-resistant. The slow pace of developing new antibiotics that specifically target Klebsiella pneumoniae can hinder effective treatment strategies.

The challenge is further accentuated in cases of KPC-producing Klebsiella pneumoniae, where treatment options are limited. In such cases, a microbiology laboratory must run specific tests to determine which antibiotics would be effective in treating the infection. It is recommended that patients with KPC-KP infections receive treatment with two or more drugs that display activity against the isolate. This approach has been shown to improve survival rates in such patients. Thus, owing to the above factors, the market is expected to hamper over the forecast period.

Segment Analysis

The global klebsiella pneumoniae infections market is segmented based on infection type, drug class, distribution channel, and region.

The Urinary Tract Infections (UTIs) from the Infection Type Segment Accounted for Approximately 45.9% of the Klebsiella Pneumoniae Infections Market Share

A urinary tract infection (UTI) is a bacterial infection that affects any part of the urinary system, including the kidneys, bladder, ureters, and urethra. It is a common condition that affects people of all ages and genders, although it is more prevalent in women due to anatomical differences.

UTIs are primarily caused by bacteria entering the urinary tract. The most common fugitive is Escherichia coli (E. coli), which is a type of bacteria that normally resides in the intestines but can travel to the urinary tract and cause infection. Other bacteria, such as Klebsiella and Proteus species, can also be responsible for UTIs.

UTIs can present with a range of symptoms, including frequent or painful urination, cloudy or bloody urine, and a strong and persistent urge to urinate. In some cases, individuals may experience fever, chills, and lower back or abdominal pain. If left untreated, UTIs can lead to more serious complications, including kidney damage and sepsis.

Treatment for UTIs typically involves a course of antibiotics. The specific antibiotic and duration of treatment depend on the type and severity of the infection. In addition to antibiotics, individuals can take steps to prevent UTIs, such as staying hydrated, urinating frequently, and wiping from front to back after using the bathroom.

Furthermore, the increasing prevalence of Urinary Tract Infections (UTIs), the increasing clinical trials of UTI drugs by the market players, and rising FDA approvals are the factors expected to drive the market segment over the forecast period.

For instance, on January 03, 2022, Spero Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis, caused by susceptible microorganisms.

Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP), Fast Track, and Priority Review designations for these cUTI indications. The Agency is planning to hold an Advisory Committee meeting to discuss this application and has also set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022.

Additionally, on November 3, 2022, GSK plc announced that the pivotal phase III EAGLE-2 and EAGLE-3 trials evaluating gepotidacin, an investigational treatment for uncomplicated urinary tract infection (uUTI) in female adults and adolescents, will stop enrolment early for efficacy following a recommendation by the Independent Data Monitoring Committee (IDMC). This decision was based on a pre-specified interim analysis of efficacy and safety data in over 3000 patients across the trials. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.6% of the Market Share in 2022, Owing to the Increasing Research for New Therapies For Antibiotic-Resistant Klebsiella, the Rising Clinical Trials for Drugs, Increasing Funding to Develop a New Vaccine

North America region is expected to hold the largest market share over the forecast period owing to the new therapies for antibiotic-resistant Klebsiella, the rising clinical trials for drugs, and increasing funding to develop a new vaccine.

For instance, on May 6, 2022, Evofem Biosciences, Inc. announced that new data from the Phase 3 AMPOWER clinical trial of Phexxi (lactic acid, citric acid, and potassium bitartrate) showed that women enrolled in the AMPOWER trial had fewer urinary tract infections (UTIs) compared to the general population.

Moreover, on May 18, 2023, a study was conducted by researchers from Washington University School of Medicine in collaboration with Omniose to explore the efficacy of bioconjugate vaccines for hypervirulent and drug-resistant strains of Klebsiella in mice. The study, which was published in PLoS Pathogens, aimed to enhance the immune response by connecting sugars on the surface of Klebsiella to proteins.

The research team tested two types of vaccines, one targeting the O-antigen and the other targeting the K-antigen. The capsule vaccine displayed exceptional efficacy in safeguarding mice against Klebsiella infections in the lungs and bloodstream. The study's findings have promising implications for the development of an effective vaccine against Klebsiella infections. Thus, owing to the above factors, the North America region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the klebsiella pneumoniae infections market include: Pfizer Inc., Novartis AG, AdvaCare Pharma, Merck & Co., Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Aurobindo Pharma Colombia, Par Pharmaceutical, AbbVie, and Actavis among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has brought about significant challenges to public health worldwide, with the emergence of various variants of the virus posing additional threats. One particular concern is the presence of Klebsiella pneumoniae bacteria in individuals infected with COVID-19, which can complicate patient management, especially in critically ill cases. This bacterium is known for its resistance to multiple antibiotics, making it challenging to treat and potentially leading to adverse outcomes.

Reports have highlighted the occurrence of K. pneumoniae co-infections, particularly among severely ill COVID-19 patients during their hospital stay. While extensive antibiotic use for initial COVID-19 diagnosis may reduce bacterial co-infections, it can also contribute to antibiotic resistance, particularly in strains of K. pneumoniae. Therefore, accurate identification of multidrug-resistant K. pneumoniae is crucial for effectively diagnosing and treating COVID-19 patients. Managing K. pneumoniae is also essential to minimizing COVID-19 risks.

Initially, co-infection studies among COVID-19 patients were limited, but they have gained significance due to varying interpretations of COVID-19 severity and mortality rates. Research has revealed a wide spectrum of co-infection rates in SARS-CoV-2 patients, ranging from 0.6% to 50%. Co-infections, mainly bacterial, have emerged as a significant factor in COVID-19-related deaths, with 50% of fatalities linked to secondary bacterial co-infections contracted during hospitalization.

Antibiotic usage to manage COVID-19 symptoms can potentially foster antibiotic resistance, and K. pneumoniae co-infection stands out due to its association with severe respiratory issues and mortality. Multidrug-resistant and extremely drug-resistant strains of this bacterium have been detected, posing a significant challenge to patient management. In Saudi Arabia, K. pneumoniae and A. baumannii were prevalent among COVID-19 patients, showing resistance to various antibiotics except colistin.

Therefore, the emergence of COVID-19 variants poses global health challenges, with attention drawn to the presence of K. pneumoniae co-infections, particularly in critically ill patients. Addressing this issue requires accurate detection of multidrug-resistant strains and efforts to control antibiotic resistance. Healthcare providers must remain vigilant in managing patients with COVID-19, including the identification and management of bacterial co-infections to improve patient outcomes.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine conflict could disrupt healthcare infrastructure, exacerbating infectious diseases like Klebsiella pneumonia in affected regions. Conflict-related population displacement could also cause overcrowded living conditions, facilitating the spread of bacterial infections due to limited access to sanitation and healthcare services.

For instance, in 2023, researchers from Lund University in Sweden collaborated with Ukrainian microbiologists to investigate antibiotic resistance in patients wounded by war and receiving treatment in hospitals. The findings, published in The Lancet Infectious Diseases, unveiled a significant prevalence of highly antibiotic-resistant bacteria among these patients.

Professor Kristian Riesbeck, a Clinical Bacteriology expert at Lund University, expressed astonishment at encountering such extreme resistance, even with his extensive experience in bacterial infections. Dr. Oleksandr Nazarchuk, a microbiologist from Ukraine, sought urgent assistance from Professor Riesbeck's team to assess antibiotic resistance in severely injured patients due to the ongoing conflict.

The study encompassed 141 individuals affected by the war, revealing concerning patterns of resistance, including Klebsiella pneumoniae, a bacterium of particular concern due to its ability to cause severe illness. The above factors are expected to have little influence over the global klebsiella pneumonia infections market growth over the forecast period.

By Infection Type

  • Pneumonia
  • Urinary Tract Infections (UTIs)
  • Bloodstream Infections
  • Intra-Abdominal Infection
  • Wound Infections

By Drug Class

  • Beta-Lactams
    • Clavulanic Acid
    • Sulbactam
    • Tazobactam
    • Avibactam
    • Vaborbactam
  • Aminoglycoside
    • Gentamicin
    • Tobramycin
    • Amikacin
    • Streptomycin
    • Others
  • Quinolones
    • Ciprofloxacin (Cipro)
    • Levofloxacin
    • Moxifloxacin
    • Ofloxacin
    • Norfloxacin
    • Gemifloxacin
    • Others
  • Cephalosporins
    • Ceftriaxone
    • Cefotaxime
  • Carbapenems
    • Imipenem/cilastatin
    • Meropenem
    • Doripenem
    • Ertapenem

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On September 22, 2022, GSK plc and Spero Therapeutics, Inc. announced they have entered into an exclusive license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic being developed by Spero, as the first oral carbapenem antibiotic to potentially treat complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.
  • On October 4, 2020, CARB-X announced it is awarding up to US$2.5 million to GangaGen Biotechnologies, headquartered in Bangalore, India, to develop novel antibacterial proteins, called klebicins, to treat pneumonia caused by Klebsiella pneumoniae, a difficult-to-treat bacteria belonging to the Enterobacterales family of Gram-negative pathogens. GangaGen will be eligible for an additional $8.1 million in funding from CARB-X if project milestones are met, subject to available funds.
  • On June 15, 2022, Shionogi & Co., Ltd. And the Global Antibiotic Research and Development Partnership (GARDP) partnered to enhance global access to cefiderocol, an antibiotic that is effective against challenging Gram-negative bacterial infections and may resist other treatments.

Cefiderocol is endorsed by the World Health Organization and approved by regulatory bodies and targets priority pathogens. This partnership involves a pharmaceutical company collaborating with a public health-focused non-profit organization. GARDP will oversee the manufacturing and distribution of cefiderocol in countries with limited access to modern antibiotics, spanning low- to upper-middle-income nations, encompassing about 70% of the world's countries and a significant portion of populations vulnerable to antibiotic resistance.

DataM Intelligence Opinion:

According to the DataM Intelligence, the emergence of antibiotic-resistant strains of Klebsiella pneumoniae has created a pressing need for novel treatment options. Efforts to combat drug-resistant bacteria include research and clinical trials, as well as the potential introduction of new antibiotics like BWC0977. The market is driven by factors such as urgency to address antibiotic resistance, approval of new treatment options, and advancements in diagnostic techniques like SERS spectroscopy combined with deep learning analysis.

Challenges remain, particularly in cases of KPC-producing K. pneumoniae where treatment options are limited. The impact of global events like the Russian-Ukraine conflict and the COVID-19 pandemic on the market dynamics could create uncertainties in certain regions. Therefore, the market for K. pneumoniae infections is evolving rapidly, with a focus on research, innovation, and collaboration to address the growing threat of antibiotic resistance and improve patient care.

Why Purchase the Report?

  • To visualize the global klebsiella pneumoniae infections market segmentation based on infection type, drug class, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of klebsiella pneumoniae infections market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global klebsiella pneumoniae infections market report would provide approximately 61 tables, 61 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Infection Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancements in Treatment Options for Managing Klebsiella Pneumoniae Infections
      • 4.1.1.2. The Rising Number of Clinical Trials Focused on Addressing Klebsiella Pneumoniae Infections
      • 4.1.1.3. Rapid Prediction of Multidrug-Resistant Klebsiella Pneumoniae through Deep Learning Analysis of SERS Spectra
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Treatment Options for KPC-Producing Klebsiella Pneumoniae
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Patent Analysis
  • 5.7. Russian-Ukraine Conflict Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Infection Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 7.1.2. Market Attractiveness Index, By Infection Type
  • 7.2. Pneumonia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Urinary Tract Infections (UTIs)
  • 7.4. Bloodstream Infections
  • 7.5. Intra-Abdominal Infection
  • 7.6. Wound Infections

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Beta-Lactams*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Clavulanic Acid
    • 8.2.4. Sulbactam
    • 8.2.5. Tazobactam
    • 8.2.6. Avibactam
    • 8.2.7. Vaborbactam
  • 8.3. Aminoglycoside
    • 8.3.1. Gentamicin
    • 8.3.2. Tobramycin
    • 8.3.3. Amikacin
    • 8.3.4. Streptomycin
    • 8.3.5. Others
  • 8.4. Quinolones
    • 8.4.1. Ciprofloxacin (Cipro)
    • 8.4.2. Levofloxacin
    • 8.4.3. Moxifloxacin
    • 8.4.4. Ofloxacin
    • 8.4.5. Norfloxacin
    • 8.4.6. Gemifloxacin
    • 8.4.7. Others
  • 8.5. Cephalosporins
    • 8.5.1. Ceftriaxone
    • 8.5.2. Cefotaxime
  • 8.6. Carbapenems
    • 8.6.1. Imipenem/cilastatin
    • 8.6.2. Meropenem
    • 8.6.3. Doripenem
    • 8.6.4. Ertapenem

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Pfizer Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Novartis AG
  • 12.3. AdvaCare Pharma
  • 12.4. Merck & Co., Inc.
  • 12.5. Ortho-McNeil-Janssen Pharmaceuticals, Inc.
  • 12.6. Teva Pharmaceuticals USA, Inc.
  • 12.7. Aurobindo Pharma Colombia
  • 12.8. Par Pharmaceutical
  • 12.9. AbbVie
  • 12.10. Actavis

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us